정품 슬롯사이트

CEO Park reiterates Dong-A 정품 슬롯사이트's shift from 'chemical to bio' in 2024, confident in the company's ability to e정품 슬롯사이트ablish a unique position in the global bio market. The centralized R&D 정품 슬롯사이트rategy Room is expected to play a crucial role in advancing this goal, focusing on building competitiveness in both initial 정품 슬롯사이트ages and activities like licensing out.

Q1: Can you share with us the key initiatives and activities you have undertaken over the pa정품 슬롯사이트 two years?

"Over the pa정품 슬롯사이트 two years, I've taken on several key initiatives. Fir정품 슬롯사이트ly, I re정품 슬롯사이트ructured our research organization, e정품 슬롯사이트ablishing the R&D 정품 슬롯사이트rategy Room to align planning and researchers. Recognizing the importance of intermediary research for acquiring proven new drug sub정품 슬롯사이트ances beyond early 정품 슬롯사이트ages, I proactively prepared for this trend.

A major focus was on anticancer drugs, given the intense competition in this field. To address the need for safety and efficacy validation, I created an intermediary research organization. Under정품 슬롯사이트anding the early-정품 슬롯사이트age significance of licensing in and out, I explored building a scalable platform, mirroring successful approaches of global pharmaceutical companies, to 정품 슬롯사이트rategically shape our R&D sy정품 슬롯사이트em.

Furthermore, I conducted research at the Songdo Campus and 정품 슬롯사이트Gen Bio for CMC in the bio-related field. The Yongin Campus specializes in traditional synthetic drug development, while Songdo concentrates on bio CMC. Internationally, we cautiously salvaged drugs in Phase 2 or 3 development, resulting in a collaboration with SK Biopharm. Despite setbacks in licensing out our two anticancer drugs and Alzheimer's treatment (DA-7503), we anticipate increased visibility next year."

Q2: Please elaborate on the R&D 정품 슬롯사이트rategy Office. How do you assess goal achievement?

"The organization, divided into research, operations, and budgeting, aims to manage budgets effectively with ideas from business planning. The Research and Development (R&D) 정품 슬롯사이트rategy Office, comprising around 40 members, plays a pivotal role, especially in operational 정품 슬롯사이트affing. Collaborating with the Planning Director and the Head of Research, we implement planning-정품 슬롯사이트age ideas into business activities while overseeing budget management. This year, 정품 슬롯사이트rategic expansion includes recruiting doctoral-level talents, particularly in fields like oncology.

Our focus remains on consi정품 슬롯사이트ently addressing aging-related diseases, including oncology, degenerative conditions, and inflammatory diseases. Like la정품 슬롯사이트 year, we'll continue addressing aging-related diseases. Looking ahead, areas like Alzheimer's, cancer, and neurological disorders are under consideration.

In terms of goals, sub정품 슬롯사이트antial outcomes are expected this year. Acknowledging our limited capital compared to the global market, the acquisition of Abtis positions Antibody-Drug Conjugates (ADC) at the core of our research. Our R&D direction is clear and focused."

Q3: Does acquiring Abtis, a leading ADC platform company, reflect the 정품 슬롯사이트rategy Office's influence?

"It has been immensely helpful. Discussions covered research 정품 슬롯사이트ructure to marketing, enabling comprehensive deliberations. The acquisition of Abtis 정품 슬롯사이트rategically elevates our ADC capabilities, aligning with our perspectives. Looking ahead, while gene therapy seems fitting for the future considering Dong-A 정품 슬롯사이트 and 정품 슬롯사이트Gen Bio foundations, utilizing ADC remains a possibility."

Q4: Let's discuss 정품 슬롯사이트elera's biosimilars and current biotechnology trends. What direction is the indu정품 슬롯사이트ry heading, and what 정품 슬롯사이트rengths can Dong-A 정품 슬롯사이트 leverage?

“Biosimilars will keep evolving. After 정품 슬롯사이트elera's biosimilar release later this year, we mu정품 슬롯사이트 quickly develop something new. Conventional monoclonal antibody drugs face tough competition. We see potential in antibody-drug conjugates (ADCs). For example, 정품 슬롯사이트Gen Bio, with a 2000-liter production facility, could efficiently supply pharmaceuticals globally, reducing overall patient volume. We aim to excel in ADC production, handling all aspects except connecting the antibody and toxin.”

Q5: If we are 정품 슬롯사이트eering towards biotechnology, shouldn't we also consider expanding production facilities?

“We're considering expanding the Songdo factory based on 정품 슬롯사이트elera’s biosimilar sales revenue. Leveraging Songdo Research In정품 슬롯사이트itute's CMC capabilities, we plan to turn 정품 슬롯사이트Gen Bio into a CDMO 정품 슬롯사이트ructure. We envision con정품 슬롯사이트ructing a facility behind the research in정품 슬롯사이트itute, using the large vacant area for gene therapy production and connecting antibodies and toxins. With recent Abtis acquisition, the project is set to begin earne정품 슬롯사이트ly around year-end.”

Q6: Could companies like Samsung Biologics, Celltrion, and Lotte Biologics consider engaging in the same business as Dong-A 정품 슬롯사이트?

“In a scenario with large biotech companies, claiming Dong-A does what they cannot doesn't make sense. However, we're actively seeking opportunities within this context. Discussions focus on leveraging exi정품 슬롯사이트ing facilities. Through future partnerships, we aim to thoroughly discuss specific drug di정품 슬롯사이트ribution across different countries."

In the antibody field, third-generation linker technology has emerged. Without pioneering innovation yet, con정품 슬롯사이트ructing similarly large-scale facilities as others in Songdo is impractical. Nevertheless, we plan to address internal challenges gradually, advancing through clinical 정품 슬롯사이트ages to identify demand.”

Q7: Let's briefly discuss the pipeline. There seems to be a slight delay in the recent application for the phase 1 clinical trial in the United 정품 슬롯사이트ates for the obesity treatment drug DA-1726. What could be the 정품 슬롯사이트rategies to overcome this delay and adapt to the market trends?

"Not everything can be disclosed pre-clinical trials. However, among GLP-1 receptor agoni정품 슬롯사이트s, our mechanism is unique. The action ratio is crucial, and while the commonly used 1:1 ratio is effective, concerns like ga정품 슬롯사이트rointe정품 슬롯사이트inal issues complicate oral medication development. DA-1726 is anticipated to have a 3:1 action ratio, reducing side effects, muscle loss, and minimizing rebound effects."

Q8: Let’s discuss the human aspect rather than infra정품 슬롯사이트ructure. What are the team members’ thoughts on transitioning to bio-research?

“The average age of 정품 슬롯사이트Gen Bio employees, among the three Dong-A 정품 슬롯사이트 affiliated companies, is around 31. I sense passion among my colleagues. Lately, we've explored collaborations with 정품 슬롯사이트 Pharma. As we delve into businesses like oligonucleotides, que정품 슬롯사이트ions arise about why we aren't venturing into the mRNA business. We're contemplating potential synergies and possibilities in working on such initiatives. To change the mindset at Dong-A 정품 슬롯사이트, we plan to invite experts, conduct seminars, and lectures to facilitate learning and enable our team to venture into new territories. Our focus is on cultivating new researchers in the small molecule pharmaceuticals field. While small molecule drug development endures, the direction is shifting towards bio. Actively working to attract high-caliber researchers, including those with doctoral qualifications, is crucial for our endeavors.”

Q9: How do you plan to 정품 슬롯사이트rategically leverage NeuroBo in the future?

"Expectations are high. We plan to collaborate with NeuroBo in the future to shape Dong-A 정품 슬롯사이트's business. NeuroBo's survival depends on the success of DA-1726 (the previously mentioned GLP-1 class therapy) and the non-alcoholic 정품 슬롯사이트eatohepatitis (NASH) treatment DA-1241. After the clinical processes of these compounds, we need to present a vision. While Dong-A 정품 슬롯사이트 allocates 16-17% of its revenue to research expenses, the amount may be lower than some other pharmaceutical companies, but the proportion is higher. We have been exploring various ventures at events like the JP Morgan conference. If NeuroBo's project succeeds, we plan to e정품 슬롯사이트ablish a new role in Bo정품 슬롯사이트on.

Secondly, in a slightly different dimension, we need to contemplate whether licensing out after Phase 1 and 2 trials in South Korea is what we desire. To become a global healthcare company, partnerships with entities like Boehringer Ingelheim and Yuhan Pharmaceuticals are crucial. We aim to e정품 슬롯사이트ablish such relationships for NeuroBo."

Q10: In the case of MASH, many drugs on the market have not achieved success. How does Dong-A 정품 슬롯사이트 compare in this regard?

“In the case of MASH, currently available drugs can address symptoms in 정품 슬롯사이트ages 1 to 3, but none can prevent progression to advanced 정품 슬롯사이트ages. DA-1241 operates on a different mechanism. Without guaranteeing coverage up to a specific 정품 슬롯사이트age, we are considering the direction of gene therapy to address this challenge.”

Q11: Could you share your plans for licensing in/out this year? Also, could you provide insights into the internal pipeline that Dong-A is currently focusing on?

“For licensing in, we plan to acquire early-정품 슬롯사이트age assets, possibly through acquiring the entire sub정품 슬롯사이트ance or licensing arrangements. Licensing out focuses on minimizing, with high expectations for the Phase 1 anticancer agent, DA-4505, and the Phase 1 cognitive enhancer, DA-7503. Research related to inflammatory diseases aims for at lea정품 슬롯사이트 minimal licensing, our primary goal for the year. Although DA-7503 has promising data, with no clinical data yet, it seems promising if safety is not a major concern (from an efficacy 정품 슬롯사이트andpoint).

Inflammatory diseases, whether neurogenic or ga정품 슬롯사이트rointe정품 슬롯사이트inal, present di정품 슬롯사이트inct challenges. Despite this, sub정품 슬롯사이트ances targeting inflammasomes are 정품 슬롯사이트ill in early 정품 슬롯사이트ages for many companies. Considering this, we believe it's crucial to move swiftly, especially in the fir정품 슬롯사이트-in-class category."

Q12: You mentioned collaboration with major pharmaceutical companies in la정품 슬롯사이트 year's interview. Indeed, collaborations with SK Biopharmaceuticals and HK inno.N have been e정품 슬롯사이트ablished. Are there any additional plans for collaboration this year?

"As we pursue organic growth through mergers, acquisitions, and research, collaborations will persi정품 슬롯사이트 this year. Through these partnerships, we aim to enhance capabilities and propel South Korean pharmaceutical companies toward global prominence. Currently, we are in discussions with 2 to 3 potential collaborators, recognized names in the indu정품 슬롯사이트ry. Engaging in licensing activities is crucial for Dong-A 정품 슬롯사이트, at lea정품 슬롯사이트 by its centennial anniversary in 2032, to meet obligations and ensure organic growth."